Risk Factors of Respiratory Failure in the Dermatomyositis Patients with Interstitial Lung Disease
Abstract
To reveal the clinical features of respiratory failure (RF) in dermatomyositis (DM) patients with interstitial lung disease (ILD), and to explore risk factors of RF in these patients. Methods The medical data of 122 DM patients with ILD were retrospectively reviewed: 40 developed RF (RF group), 82 did not develope RF (Non RF group). Clinical, laboratory and radiological variables were compared between RF patients and Non RF patients. Multivariate Logistic regression was used to analyze risk factors of RF. Results In RF patients, the female-male ratio was 3∶1, the median age at DM onset was 49.5 （42.3-58.6) years-old. There were 67.5%, 85.0% and 95.0% patients developed RF within 6 months, 1 year and 2 years after the onset of DM. The factors significantly associated with RF included DM onset age, clinically amyopathic dermatomyositis (CADM), pneumomediastinum (PNM), aspartate aminotransferase(AST), lactate dehydrogenase (LDH), albumin, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, anti-Jo-1 antibody presence and ground-glass opacities sign (POR)=1.791, P=0.025〕, higher AST level (OR=1.937, P=0.048), CADM diagnosis (OR=3.881, P=0.007) and ground-glass opacities sign (OR=4.187, P=0.014) were independent risk factors of RF in DM patients with ILD. ConclusionsRF occurs more often within 2 years of DM onset. The DM patients with older DM onset age, elevated AST level, CADM diagnosis or ground-glass opacities sign took higher risks for RF development.
Keywords: DermatomyositisLung diseases, interstitial, Respiratory insufficiency
Full Text:
PDFReferences
PENG JM. DU B, WANG Q. et al. Dermatomyositis and Polymyositis in the intensive care unit: a single-center retrospective cohort study of 102 patients. PLoS One,2016, 11(4); e0154441 [2017-07-21]. https://doi. org/10. 1371/ journal, pone. 0154441.
SHERER Y, SHEPSHELOVICH D. SHALEV T, et al. Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol, 2007, 26 ( 11 ): 1851- 1855.
BOHAN A, PETER JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975,292(7) ;344-347. SONTHEIMER RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol,2002,46(4);626-636.
GERAMI P, SCHOPE JM, MCDONALD L. et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol,2006,54(4):597-613,
RAGHU G, COLLARD HR. EGAN JJ , et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011 ,183(6); 788- 824.
LAMBA TS, SHARARA RS, SINGH AC, et al. Pathophysiology and classification of respiratory failure. Crit Care Nurs Q.2016,39(2):85-93.
FATHI M, VIKGREN J, BOIJSEN M. et al. Interstitial lung disease in polymyositis and dermatomyositis;longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum, 2008,59(5):677-685.
CHENIJ. TSAI WP, WU YJ , et al. Infections in polymyositis and dermatomyositis; analysis of 192 cases. Rheumatology (Oxford) ,2010,49(12) :2429-2437.
FANG YF, WU YJ. KUO CF, et al. Malignancy in dermatomyositis and polymyositis; analysis of 192 patients. Clin Rheumatol,2016,35(8): 1977-1981.
FATHI M, LUNDBERG IE, TORNLING G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med,2007,28(4) ;451-458.
MARIE I, HATRON PY. DOMINIQUE S. et al. (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis:a series of 107 patients. Arthritis Rheum,2011,63( 11):3439-3447.
SPATH M. SCHRODER M, SCHLOTTER-WEIGEL B. et al. The long-term outcome of anti-Jo-l-positive inflammatory myopathies. J Neurol,2004,251 (7);859-864.
PIRODDI IM. FERRAIOLI G, BARLASCINI С , et al. Severe respiratory failure as a presenting feature of an interstitial lung disease associated with anti-synthetase syndrome (ASS). Respir Investig,2016,54(4):284-288.
XU Y, YANG CS, LI YJ ,et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol, 2016, 35 ( 1 ): 113-116.
GALIMBERTI F. LI Y, FERNANDEZ AP. Clinically amyopathic dermatomyositis; clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol, 2016,174 (1):158-164.
MUKAEH, ISHIMOTO H. SAKAMOTO N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest ,2009,136(5): 1341-1347.
YE S, CHEN XX, LU XY. et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease;a retrospective cohort study. Clin Rheumatol, 2007, 26( 10): 1647-1654.
SATO S, HIRAKATA M. KUWANA M , et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum,2005,52(5); 1571-1576.
KOBAYASHI N, TAKEZAKI S, KOBAYASHI I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) ,2015,54(5); 781- 791.
KIVANC T, KULAKSIZOGLU S, LAKADAMYAL1 H, et al. Importance of laboratory parameters in patients with obstructive sleep apnea and their relationship with cardiovascular diseases. J Clin Lab Anal,2017[2017-07-21]. https://doi. org/10. 1002/jcla. 22199
OZTURK ZA, KUYUMCU ME. YESIL Y, et al. Is there a link between neutrophil-lymphocyte ratio and microvascular complications in geriatric diabetic patients? J Endocrinol Invest,2013,36(8): 593-599.
ARTAQM, UYSAL M, KARAA gAQ M, et al. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. J Gastrointest Cancer,2017,48(2); 176-180.
YANG W, WANG X, ZHANG W. et al. Neutrophil- lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis. Clin Chim Acta, 2017, 465; 11-16 [2017-10-23]. http;//doi: 10. 1016/j. cca. 2016. 12.007.
Refbacks
- There are currently no refbacks.
